Eli Lilly Boosts Annual Forecasts as GLP-1 Drug Surge Drives US Stock Market Gains.

Eli Lilly has recently updated its annual profit and revenue forecasts following a robust first quarter performance fueled by the continued demand for its weight-loss and diabetes medications, Zepbound and Mounjaro. The company launched its oral GLP-1 pill, Foundayo, which adds a novel option to its portfolio and enhances its market presence. CEO David Ricks noted that 2026 is showing promising signs of growth, particularly as Foundayo could significantly expand the addressable market for GLP-1 treatments, positioning Lilly favorably against competitors such as Novo Nordisk in the expanding GLP-1 agonist market, projected to exceed $150 billion in revenue in the coming decade.

Lilly’s adjusted earnings for the first quarter reached $8.55 per share, which is substantially above analyst expectations of $6.66. Sales figures were similarly impressive, with Mounjaro generating $8.7 billion and Zepbound bringing in $4.2 billion, both exceeding market estimates. The company’s optimistic adjustments in its earnings forecast—from $33.50 to $35 per share to a new range of $35.50 to $37.00—shows confidence in its strategies to mitigate the impacts of lower realized prices and government deals affecting revenue streams.

Investor focus is now shifting towards the rollout of Foundayo, with initial prescription rates falling short of projections, leading to questions about its market penetration against Novo Nordisk’s Wegovy, which currently enjoys a first-mover advantage. While analysts initially expected approximately 8,000 prescriptions in the first week, only 3,707 were reported. This disparity highlights the critical nature of consumer adoption and illustrates the competitive landscape between injectable and oral options in the weight-loss market, as Lilly aims to capture a broader patient demographic reluctant to adopt injectable treatments.

Source: The Economic Times

(Expert Note: This report was prepared by the Wealthova team.)